Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort

被引：0
|
作者：
Phillip Chan
Orlanda Goh
Eugène Kroon
Donn Colby
Carlo Sacdalan
Suteeraporn Pinyakorn
Peeriya Prueksakaew
Peter Reiss
Jintanat Ananworanich
Victor Valcour
Serena Spudich
Robert Paul
机构：
[1] SEARCH,United States Military HIV Research Program
[2] The Thai Red Cross AIDS Research Centre,Department of Global Health, Amsterdam University Medical Centers
[3] The Henry M. Jackson Foundation for the Advancement of Military Medicine,Memory and Aging Center, Department of Neurology
[4] Walter Reed Army Institute of Research,Center for Neuroepidemiology and Clinical Neurological Research
[5] University of Amsterdam,Missouri Institute of Mental Health
[6] and Amsterdam Institute for Global Health and Development,undefined
[7] University of California San Francisco,undefined
[8] Yale University,undefined
[9] University of Missouri-St. Louis,undefined
来源：
AIDS Research and Therapy | / 17卷
关键词：
Dolutegravir; Neuropsychiatric adverse events; Depression; RV254; Cognitive performance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Impact on bone mineral density after 2 years of switching to four dolutegravir-based triple or dual regimens
    Piscaglia, M.
    Gallazzi, I.
    Restelli, S.
    Baldin, G.
    Paladini, L.
    Cossu, M.
    Di Giambenedetto, S.
    Rizzardini, G.
    Capetti, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [32] Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study
    Fernandez-Bargiela, Noelia
    Rotea-Salvo, Sandra
    Margusino-Framinan, Luis
    Balboa-Barreiro, Vanesa
    Martin-Herranz, Isabel
    Castro-Iglesias, Angeles
    Mena-De-Cea, Alvaro
    Lopez-Calvo, Soledad
    Vazquez-Rodriguez, Pilar
    Miguez-Rey, Enrique
    Cid-Silva, Purificacion
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (04) : 207 - 211
  • [33] Impact of switching to a dolutegravir-based regimen on body weight changes: insights from West African adult HIV cohorts
    Tiendrebeogo, Thierry
    Malateste, Karen
    Poda, Armel
    Minga, Albert
    Lahiri, Cecile D.
    Ezechi, Oliver
    Ekouevi, Didier K.
    Ofotokun, Igho
    Jaquet, Antoine
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 (12)
  • [34] Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and their Outcomes after Treatment Change: a pharmacogenetic study
    Cusato, Jessica
    Borghetti, Alberto
    Teti, Elisabetta
    Milesi, Maurizio
    Tettoni, Maruia Cristina
    Bonora, Stefano
    Trunfio, Mattia
    D'avolio, Antonio
    Compagno, Mirko
    Di Giambenedetto, Simona
    Di Perri, Giovanni
    Calcagno, Andrea
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 1304 - 1305
  • [35] Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study
    Cusato, Jessica
    Borghetti, Alberto
    Teti, Elisabetta
    Milesi, Maurizio
    Tettoni, Maria Cristina
    Bonora, Stefano
    Trunfio, Mattia
    D'Avolio, Antonio
    Compagno, Mirko
    Di Giambenedetto, Simona
    Di Perri, Giovanni
    Calcagno, Andrea
    METABOLITES, 2022, 12 (12)
  • [36] Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa
    Mpofu, Rephaim
    Kawuma, Aida N.
    Wasmann, Roeland E.
    Akpomiemie, Godspower
    Chandiwana, Nomathemba
    Sokhela, Simiso Mandisa
    Moorhouse, Michelle
    Venter, Willem Daniel Francois
    Denti, Paolo
    Wiesner, Lubbe
    Post, Frank A.
    Haas, David W.
    Maartens, Gary
    Sinxadi, Phumla
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (05) : 1247 - 1257
  • [37] Is treatment emergent weight gain on dolutegravir-based antiretroviral therapy reversible following discontinuation? A retrospective cohort study
    Ring, K.
    Freeman, C.
    Weston, R.
    Fidler, S.
    Mackie, N.
    HIV MEDICINE, 2020, 21 : 24 - 24
  • [38] Reasons, Efficacy and Safety of Switching to Dolutegravir-Based Regimens Among Virologically Suppressed PLWH: A Retrospective Cohort Study of 96 Weeks
    Deng, Meiju
    Chen, Na
    Lao, Xiaojie
    Wang, Xiaolei
    Fu, Jiantao
    Xing, Lulu
    Zhao, Hongxin
    INFECTION AND DRUG RESISTANCE, 2024, 17 : 1571 - 1582
  • [39] Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens
    Rodrigues, Janine
    Lowton, Karishma
    SOUTH AFRICAN JOURNAL OF PSYCHIATRY, 2023, 29
  • [40] Metabolic Syndrome and Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy in Northern Tanzania
    Mirai, Tumaini E.
    Kilonzo, Kajiru G.
    Sadiq, Abid M.
    Muhina, Ibrahim Ali Ibrahim
    Kyala, Norman J.
    Marandu, Annette A.
    Gharib, Sarah K.
    Costantine, Andrea R.
    Mkwizu, Elifuraha W.
    Howlett, William P.
    Shao, Elichilia R.
    Nyakunga, Gissela B.
    Akrabi, Huda F.
    Kshettry, Vibhu R.
    Maro, Venance P.
    Chamba, Nyasatu G.
    Lyamuya, Furaha S.
    JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE, 2024, 23
12345